FOLH1 and Familial prostate cancer: 225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells, has shown remarkable therapeutic efficacy in heavily pretreated mCRPC patients (7–11).